Skip to content
OpenCapital
Get started

Climb Bio, Inc. CLYM Q1 2026 earnings

Reported May 7, 2026 · Before market open

EPS-$0.20Beat by $0.06
EPS estimate-$0.26

Next report

Aug 11, 2026 (In 1 week)
EPS estimate-$0.22

Financials

Q1 2026

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$732.39M+577%
Enterprise value$724.52M+742%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0×0.0×
Current ratio27.9×+13.6×

Versus estimates

Diluted EPS

Q1 2026-$0.20Beat by $0.06
Q4 2025-$0.26Miss by $0.06Q3 2025-$0.19Miss by $0.03Q2 2025-$0.13Beat by $0.06Q1 2025-$0.31Miss by $0.16Q4 2024-$0.13Beat by $0.02

Ask the moment Climb Bio, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Climb Bio, Inc. report Q1 2026 earnings?
Climb Bio, Inc. (CLYM) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Climb Bio, Inc.'s Q1 2026 revenue and EPS?
Climb Bio, Inc. reported eps of $-0.20 for Q1 2026.
Did Climb Bio, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.26 by $0.06.
How did Climb Bio, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 35.5% from $-0.31.
Where can I find Climb Bio, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-205079) and the 10-Q periodic report (0001193125-26-210357) directly on SEC EDGAR. The filing index links above go to sec.gov.